Replies to post #973 on Trillium Therapeutics Inc (TRIL)

[LongRun8]

TRIL rose 2.7% after a Nasdaq delisting notice indicated that the sale to Pfizer (NYSE:PFE) was tentatively scheduled to close prior to market open tomorrow. The stock is expected to be halted this evening, according to the notice. In late August Pfizer agreed to buy Trillium, a clinical stage immuno-oncology company, in a $2.3B deal. Under the terms of the agreement, Pfizer agreed to buy Trillium for an implied $18.50/share, in cash. The delisting notices comes as Trillium's HSR deadline for the Pfizer deal was scheduled to expire. Trillium didn't immediately return Seeking Alpha request for comment on the status of HSR. Last week, Trillium Therapeutics (TRIL) receives final court order approving arrangement.

From Seeking Alpha

[swampboots]

TRIL I did not follow closely but great insight by you to invest in this CD-47 "player" (as hundreds of other strategies always compete for attention), and clearly closer causation my link yesterday pronounced:

"Turning off this pathway—a checkpoint interaction between a protein called SIRPa on the macrophage and the CD47 protein found on all 'self' cells—was the key to creating this therapy."